Study of Efficacy and Safety of Ormeloxifene in the Management of Dysfunctional Menorrhagia

Abstract

ABSTRACTObjectiveTo assess the efficacy and safety of ormeloxifene in the medical management of dysfunctional menorrhagia.MethodologyFifty women with menorrhagia were recruited for the study. Ormeloxifene 60 mg twice a week for 3 months from first day of periods and once a week for next 3 months was given. Mean blood loss (MBL) was assessed using pictorial blood loss assessment chart (PBAC). Ultrasonography (USG) and blood hemoglobin levels were done as baseline and at 2, 4 and 6 months of treatment. Side-effects of the drug were recorded. Changes in PBAC scoring, endometrial thickness (ET) and hemoglobin levels (Hb) were analyzed by student's paired ‘t’ tests using SPSS 17.0 version. p value . 0.05 was taken as significant.ResultsThe pretreatment PBAC score was 360, which reduced to 209.5 at 2 months, 88.7 at 4 months and 68.2 at 6 months of treatment, which was statistically significant (p-value . 0.001). The rise in hemoglobin and decrease in ET, in women on ormeloxifene was also statistically significant (p-value . 0.001).ConclusionOrmeloxifene is an effective and safe therapeutic option for the medical management of menorrhagia.How to cite this articleGupta U, Shrivastava K, Katiyar G, Arif A, Gupta NK. Study of Efficacy and Safety of Ormeloxifene in the Management of Dysfunctional Menorrhagia. J South Asian Feder Menopause Soc 2014;2(1):1-4.